BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mohamady S, Galal M, Eldehna WM, Gutierrez DC, Ibrahim HS, Elmazar MM, Ali HI. Dual Targeting of VEGFR2 and C-Met Kinases via the Design and Synthesis of Substituted 3-(Triazolo-thiadiazin-3-yl)indolin-2-one Derivatives as Angiogenesis Inhibitors. ACS Omega 2020;5:18872-86. [PMID: 32775889 DOI: 10.1021/acsomega.0c02038] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Kadagathur M, Sujat Shaikh A, Panda B, George J, Phanindranath R, Kumar Sigalapalli D, Bhale NA, Godugu C, Nagesh N, Shankaraiah N, Tangellamudi ND. Synthesis of indolo/pyrroloazepinone-oxindoles as potential cytotoxic, DNA-intercalating and Topo I inhibitors. Bioorganic Chemistry 2022. [DOI: 10.1016/j.bioorg.2022.105706] [Reference Citation Analysis]
2 Alanazi MM, Elkady H, Alsaif NA, Obaidullah AJ, Alanazi WA, Al-hossaini AM, Alharbi MA, Eissa IH, Dahab MA. Discovery of new quinoxaline-based derivatives as anticancer agents and potent VEGFR-2 inhibitors: Design, synthesis, and in silico study. Journal of Molecular Structure 2022;1253:132220. [DOI: 10.1016/j.molstruc.2021.132220] [Reference Citation Analysis]
3 Alsaif NA, Taghour MS, Alanazi MM, Obaidullah AJ, Alanazi WA, Alasmari A, Albassam H, Dahab MA, Mahdy HA. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies. Bioorg Med Chem 2021;46:116384. [PMID: 34479065 DOI: 10.1016/j.bmc.2021.116384] [Reference Citation Analysis]
4 Dhokne P, Sakla AP, Shankaraiah N. Structural insights of oxindole based kinase inhibitors as anticancer agents: Recent advances. Eur J Med Chem 2021;216:113334. [PMID: 33721669 DOI: 10.1016/j.ejmech.2021.113334] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
5 Ali A, Ali A, Tahir A, Bakht MA, Ahsan MJ. Ultrasound promoted green synthesis, anticancer evaluation, and molecular docking studies of hydrazines: a pilot trial. J Enzyme Inhib Med Chem 2022;37:135-44. [PMID: 34894970 DOI: 10.1080/14756366.2021.1995727] [Reference Citation Analysis]
6 Wang DP, Liu KL, Li XY, Lu GQ, Xue WH, Qian XH, Mohamed O K, Meng FH. Design, synthesis, and in vitro and in vivo anti-angiogenesis study of a novel vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor based on 1,2,3-triazole scaffold. Eur J Med Chem 2021;211:113083. [PMID: 33340911 DOI: 10.1016/j.ejmech.2020.113083] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Nafie MS, Boraei AT. Exploration of novel VEGFR2 tyrosine kinase inhibitors via design and synthesis of new alkylated indolyl-triazole Schiff bases for targeting breast cancer. Bioorganic Chemistry 2022;122:105708. [DOI: 10.1016/j.bioorg.2022.105708] [Reference Citation Analysis]
8 El-Adl K, Abdel-Rahman AA, Omar AM, Alswah M, Saleh NM. Design, synthesis, anticancer, and docking of some S- and/or N-heterocyclic derivatives as VEGFR-2 inhibitors. Arch Pharm (Weinheim) 2021;:e2100237. [PMID: 34862655 DOI: 10.1002/ardp.202100237] [Reference Citation Analysis]